Protocols Calculator Guides Glossary About Calculator →
Research use only.  Educational reference. Not medical advice. Not for human consumption.
// catalog · v3

Peptide protocols, indexed.

Research-grade dosage protocols sourced from peer-reviewed literature. Each full protocol contains dosing tables, reconstitution math, mechanism notes, and primary citations.

100+full protocols built
100+peptides cataloged
8research categories
0vendor placements
// 01

Recovery & Tissue Repair

14 protocols
● built
BPC-157 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.7 mcg
5 mgRUO
→ open protocol
 ● built
BPC-157 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
BPC-157 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
TB-500 / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
TB-500 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
TB-500 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
KPV / 10 mg vial
Tripeptide fragment of α-MSH. Studied for anti-inflammatory properties, gut mucosa research, and NF-κB inhibition.
500 mcg–2 mg/daySub-Q · oral
→ open protocol
 ● built
LL-37 / 5 mg vial
Cathelicidin-derived antimicrobial peptide studied for immune modulation, wound healing, and antimicrobial defense.
100–500 mcg/daySub-Q
→ open protocol
 ● built
Thymosin α-1 / 1.6 mg
Immune-modulating peptide from thymosin fraction 5. Studied for immune dysregulation and immune senescence.
1.6 mg 2×/wkSub-Q
→ open protocol
 ● built
VIP / 5 mg vial
Vasoactive Intestinal Peptide. Studied for chronic inflammatory response syndrome (CIRS), immune balance, and anti-inflammatory pathways.
50–250 mcg/dayIntranasal
→ open protocol
 ● built
ARA-290 · Cibinetide / 16 mg
Erythropoietin-derived peptide. Studied for diabetic neuropathy, sarcoidosis-related small-fiber neuropathy, and tissue protection.
4–8 mg/daySub-Q
→ open protocol
 ● built
Glutathione / 600–1200 mg
Tripeptide master antioxidant. Studied for oxidative-stress reduction, hepatic detoxification support, and immune function.
600–1200 mg/doseSub-Q · IV
→ open protocol
 ● built
PNC-27 / 10 mg vial
p53-derived membrane-disrupting peptide. Studied as an investigational anti-cancer compound that selectively targets HDM-2 expressing cells.
10–50 mg/doseSub-Q · IV
→ open protocol
// 02

GH Secretagogues & Growth Hormone

17 protocols
● built
CJC-1295 (No DAC) + Ipamorelin / 10 mg blend
GHRH analog + selective GHS. Complementary pathways for synergistic pulsatile GH release.
100–300 mcg ea/dayDaily8–12 wks
→ open protocol
 ● built
Ipamorelin / 10 mg vial
First selective GH secretagogue. GH release without cortisol/ACTH elevation. Low desensitization profile.
100–300 mcg/dose1–3×/day8–16 wks
→ open protocol
 ● built
GHRP-2 · Pralmorelin / 10 mg
Potent GHRP. Strong GH stimulation via dual pituitary + hypothalamic sites. Mild cortisol/ACTH elevation at higher doses.
100–300 mcg/dose1–3×/day
→ open protocol
 ● built
GHRP-6 / 10 mg vial
Classic GHRP with the strongest appetite stimulation of any secretagogue. Cortisol elevation at high doses.
100–300 mcg/dose2–3×/day
→ open protocol
 ● built
Hexarelin / 5 mg vial
Most potent GHRP studied. Strong GH release plus cardioprotective effects. Significant desensitization at chronic high doses.
100–200 mcg/dose2–3×/day
→ open protocol
 ● built
Sermorelin / 10 mg vial
GHRH(1–29) analog. Preserves IGF-1 negative feedback. First GHRH analog studied (pediatric GHD). Before-sleep dosing.
200–500 mcg/dayBefore sleep12–24 wks
→ open protocol
 ● built
CJC-1295 DAC / 2 mg vial
Long-acting GHRH analog with Drug Affinity Complex. ~6–8 day half-life via albumin binding. Once-weekly dosing.
1–2 mg/weekWeekly
→ open protocol
 ● built
CJC-1295 NO DAC / 5 mg vial
Short-acting GHRH analog (~30 min half-life). Produces natural GH pulses. Typically combined with GHRPs.
100–300 mcg/dose1–3×/day
→ open protocol
 ● built
HGH 191AA / 24 IU vial
24 IU vial · 3 mL BAC → 8 IU/mL · 1 unit = 0.08 IU
24 IURUO
→ open protocol
 ● built
HGH 191AA / 36 IU vial
36 IU vial · 3 mL BAC → 12 IU/mL · 1 unit = 0.12 IU
36 IURUO
→ open protocol
 ● built
Tesamorelin / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
Tesamorelin / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
IGF-1 LR3 / 1 mg vial
Long-acting IGF-1 analog. Downstream GH mediator with extended receptor binding. Direct anabolic and recovery effects.
20–100 mcg/daySub-Q
→ open protocol
 ● built
PEG-MGF / 2 mg vial
PEGylated mechano growth factor. IGF-1 splice variant studied for muscle satellite cell activation and post-injury recovery.
200–400 mcg 2×/wkSub-Q
→ open protocol
 ● built
Follistatin 344 · 315 / 1 mg
Myostatin inhibitor. Studied for muscle hypertrophy via GDF-8 / activin pathway antagonism. Two main isoforms compared.
100 mcg/daySub-Q
→ open protocol
// 03

Metabolic & Weight Management

14 protocols
● built
Retatrutide / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
Retatrutide / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
 ● built
Retatrutide / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Retatrutide / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
Retatrutide / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Semaglutide / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
Semaglutide / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
Tirzepatide / 10 mg vial
10 mg vial · 2 mL BAC → 5 mg/mL · 1 unit = 50 mcg
10 mgRUO
→ open protocol
 ● built
Tirzepatide / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
Tirzepatide / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Tirzepatide / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
Tirzepatide / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
Tirzepatide / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Mazdutide / 6 mg vial
Dual GLP-1 / glucagon receptor agonist. Phase 3 weight-management investigational compound. Differentiated from triple-agonist class.
0.3–9 mg/weekWeekly
→ open protocol
 ● built
Cagrilintide / 5 mg vial
Long-acting amylin analog. Under investigation in combination with semaglutide (CagriSema). Satiety modulation.
0.3–2.4 mg/weekWeekly
→ open protocol
 ● built
AOD-9604 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.7 mcg
5 mgRUO
→ open protocol
 ● built
AOD-9604 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
5-Amino-1MQ / 50 mg vial
NNMT inhibitor studied for adipocyte reduction in metabolic syndrome models. Oral research compound.
50–100 mg/dayOral
→ open protocol
 ● built
AICAR / 50 mg vial
AMPK activator. Studied as an exercise mimetic — increasing fatty-acid oxidation and endurance capacity in preclinical models.
100–500 mg/daySub-Q
→ open protocol
 ● built
SLU-PP-332 / 10 mg vial
ERR (estrogen-related receptor) agonist. Novel exercise-mimetic compound studied for muscle endurance and fat oxidation.
10–25 mg/daySub-Q
→ open protocol
 ● built
MIC + Lipo-C + B12
Lipotropic blend of methionine, inositol, choline, plus B12. Studied for hepatic fat metabolism support and energy.
1 mL/wkIM · Sub-Q
→ open protocol
// 04

Longevity & Bioregulators

17 protocols
● built
Epitalon / 10 mg vial
10 mg vial · 2 mL BAC → 5 mg/mL · 1 unit = 50 mcg
10 mgRUO
→ open protocol
 ● built
Epitalon / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
FOXO4-DRI / 10 mg vial
FOXO4-p53 disruptor. Studied as a senolytic agent — selectively inducing apoptosis in senescent cells.
1–5 mg/injection3-day cycleMonthly
→ open protocol
 ● built
SS-31 · Elamipretide / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
SS-31 · Elamipretide / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
MOTS-c / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
MOTS-c / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
MOTS-c (40 mg vial / 4 mL Option)
40 mg vial · 4 mL BAC → 10.0 mg/mL · 1 unit = 100 mcg · 3 baseline + 3 Advanced charts
40 mg4 mLRUO
→ open protocol
 ● built
NAD+ / 500 mg vial
500 mg vial · 3 mL BAC → 167 mg/mL · 1 unit = 1.67 mg
500 mgRUO
→ open protocol
 ● built
NAD+ / 1000 mg vial
1000 mg vial · 3 mL BAC → 333 mg/mL · 1 unit = 3.33 mg
1000 mgRUO
→ open protocol
 ● built
Humanin / 5 mg vial
Mitochondrial-derived neuroprotective peptide. Studied for Alzheimer's models, metabolic regulation, and aging biomarkers.
100–250 mcg/daySub-Q
→ open protocol
 ● built
Pinealon / 20 mg vial
Tripeptide bioregulator from pineal gland. Studied for circadian regulation, sleep architecture, and neuroretinal aging.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Cartalax / 20 mg vial
Tripeptide bioregulator from cartilage. Studied for musculoskeletal aging and connective tissue gene expression.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Chonluten / 20 mg vial
Tripeptide bioregulator from bronchial mucosa. Studied for respiratory epithelial aging and pulmonary biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Bronchogen / 20 mg vial
Tetrapeptide bioregulator. Studied for bronchial epithelium repair, pulmonary function, and respiratory aging biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Prostamax / 20 mg vial
Tripeptide bioregulator. Studied for prostate-tissue gene expression and male reproductive-tissue aging biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
// 05

Skin & Cosmetic Peptides

6 protocols
● built
GHK-Cu / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
GHK-Cu / 100 mg vial
100 mg vial · 3 mL BAC → 33.3 mg/mL · 1 unit = 333 mcg
100 mgRUO
→ open protocol
 ● built
AHK-Cu / 50 mg vial
Copper tripeptide cousin of GHK-Cu. Primarily studied for hair follicle stimulation and dermal capillary health.
0.5–2 mg/dayTopical · Sub-Q
→ open protocol
 ● built
Melanotan I · Afamelanotide / 10 mg
Selective MC1R agonist. studied for erythropoietic protoporphyria. Studied for tanning and photoprotection.
0.5–1 mg/daySub-Q
→ open protocol
 ● built
Melanotan II / 10 mg vial
Non-selective melanocortin receptor agonist. Studied for skin pigmentation, photoprotection, and sexual function.
0.25–1 mg/daySub-Q
→ open protocol
// 06

Hormonal & Sexual Health

7 protocols
● built
HCG / 5000 IU vial
Human chorionic gonadotropin. LH-mimetic. studied for cryptorchidism and hypogonadism. Testosterone support and fertility research.
250–1500 IU/dose2–3×/wk
→ open protocol
 ● built
HMG / 75 IU vial
Human menopausal gonadotropin. FSH + LH combination studied for ovarian stimulation and fertility research applications.
75–150 IU/daySub-Q · IM
→ open protocol
 ● built
PT-141 · Bremelanotide / 10 mg
Melanocortin agonist (MC3R/MC4R). investigational compound studied for HSDD. CNS sexual arousal mechanism.
1.0–2.0 mg/dosePRNMax 1×/24h
→ open protocol
 ● built
Gonadorelin / 2 mg vial
GnRH decapeptide. Stimulates pulsatile LH and FSH release from pituitary. HPG axis research.
100 mcg/pulsePulsatile
→ open protocol
 ● built
Kisspeptin-10 / 10 mg vial
GPR54 receptor agonist. Upstream GnRH pulse inducer. Studied for LH pulsatility and reproductive hormone research.
1–2 nmol/kgSub-Q
→ open protocol
 ● built
Oxytocin / 10 IU vial
Nonapeptide neuromodulator. Studied for social bonding, anxiety reduction, and stress regulation. Intranasal and sub-Q routes.
5–40 IU/doseIntranasal · Sub-Q
→ open protocol
// 07

Cognitive & Neuroprotective

8 protocols
● built
Cerebrolysin / 60 mg vial
Porcine brain-derived neuropeptide mixture. Studied for neuroprotection, neuroplasticity, and recovery from neural injury.
5–30 mL/dayIV · IM10–21 day cycle
→ open protocol
 ● built
Semax / 30 mg vial
Synthetic heptapeptide ACTH analog. Studied for cognitive enhancement, neuroprotection, and BDNF upregulation.
300–600 mcg/dayIntranasal
→ open protocol
 ● built
ADAMAX / 30 mg vial
Modified Semax analog with extended half-life. Studied for cognitive enhancement, BDNF upregulation, and neuroprotective signaling.
300–600 mcg/dayIntranasal
→ open protocol
 ● built
Selank / 5 mg vial
Synthetic tuftsin analog with anxiolytic and cognitive effects. Studied for anxiety, stress, and immune function.
250–3000 mcg/dayIntranasal · Sub-Q
→ open protocol
 ● built
DSIP / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
DSIP / 15 mg vial
15 mg vial · 3 mL BAC → 5 mg/mL · 1 unit = 50 mcg
15 mgRUO
→ open protocol
 ● built
Dermorphin / 5 mg vial
Heptapeptide opioid agonist (mu-receptor). Studied as an investigational analgesic with potency multiples greater than morphine.
100–500 mcg/doseSub-Q
→ open protocol
 ● built
PE-22-28 · Spadin Analog / 10 mg
TREK-1 channel inhibitor. Studied as a fast-acting investigational antidepressant in preclinical models.
100–500 mcg/daySub-Q · Intranasal
→ open protocol
// 08

Peptide Blends

9 protocols
● built
BPC-157 + TB-500 / 20 mg blend
High-dose recovery blend: 10 mg BPC-157 + 10 mg TB-500. Standard and loading-phase protocols. Complementary tissue-repair mechanisms.
500–1000 mcg/day4–8 wks
→ open protocol
 ● built
BPC-157 + TB-500 / 10 mg blend
Lighter 10 mg version: 5 mg BPC-157 + 5 mg TB-500. For lower doses or shorter cycles.
250–500 mcg/day4–6 wks
→ open protocol
 ● built
CJC-1295 (No DAC) + Ipamorelin / 10 mg
GHRH analog + selective GHS. Synergistic pulsatile GH release via complementary receptor activation.
100–300 mcg ea/day8–12 wks
→ open protocol
 ● built
Semaglutide + Cagrilintide · CagriSema
GLP-1 agonist + amylin analog. Phase 3 investigation. Dual satiety mechanism for weight management research.
Variable titrationWeekly
→ open protocol
 ● built
GHRP-2 + CJC-1295 / 10 mg blend
Potent GHRP + GHRH combination for amplified GH pulse. Classic synergistic secretagogue pairing.
100–300 mcg ea/dose2–3×/day
→ open protocol
 ● built
Tesamorelin + Ipamorelin / 10 mg blend
GHRH analog with strongest visceral fat evidence (HIV lipodystrophy trials) + selective GHRP. Synergistic GH release.
2 mg + 300 mcg/doseDaily
→ open protocol
 ● built
4× Blend
Four-peptide stack combining tissue repair and recovery agents in a single reconstituted vial. Synergistic mechanisms for accelerated repair research.
VariableDaily
→ open protocol
 ● built
GLOW Blend
Skin & longevity blend pairing GHK-Cu with complementary peptides. Studied for collagen synthesis, skin remodeling, and gene-expression modulation.
1–2 mg/daySub-Q
→ open protocol
 ● built
KLOW Blend
Multi-peptide combination blend for systemic recovery and tissue support. Combines complementary peptide mechanisms in a single vial.
VariableDaily
→ open protocol